Additional file 2 of Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

Supplementary Material 2: Table S1. Characteristics of selected patients in 2 immunotherapy scRNA-seq cohorts and 1 ST cohort. Table S2. List of scRNA datasets applied to develop LM.SIG. Table S3. List of pan-cancer transcriptomic datasets. Table S4. List of bulk RNA-seq immunotherapy datasets. Table S5. List of CRISPR datasets. Table S6. List of LM-related genes. Table S7. ML algorithms in SurvBenchmark design. Table S8. The forward and reverse primers in RT-qPCR analysis. Table S9. List of LMx genes in each scRNA-seq dataset. Table S10. List of LMy genes in each scRNA-seq dataset. Table S11. List of LMn genes in each scRNA-seq dataset. Table S12. List of LM.SIG genes. Table S13. Comparison of AUC between LM.SIG and other well-established signatures. Table S14. Summary for computational efficiency of 15 ML algorithms. Table S15. List of enrolled 22,505 CRISPR genes in 17 datasets. Table S16. List of the top 5% of CRISPR genes over-represented in LM.SIG.